UNASSIGNED: In order to assess the OS of patients with thyroid cancer after a bone metastases carcinologic resection, a retrospective multicentric study was performed, evaluating the 1, 5, 10 and 15 years-OS along with the potential prognosis associated factors.
UNASSIGNED: 40 patients have been included in this multicentric study, with a mean follow-up after surgery of 46.6 ± 58 months. We observed 25 (62.5%) unimestastatic patients and 15 multimetastatic patients (37.5%). The median overall survival after resection was 48 ± 57.3 months. OS at 1, 5, 10, and 15 years was respectively 76.2%, 63.6%, 63.6%, and 31.8%. Survival for patients with a single bone metastasis at 15 year was 82.3%, compared with 0.0% (Log Rank, p = 0.022) for multi-metastatic bone patients.
UNASSIGNED: This study advocates for an increased long term 10-year OS in patients with thyroid cancer, after resection of a single bone metastasis, suggesting the benefits of this strategy in this population.
■为了评估骨转移癌切除术后甲状腺癌患者的OS,进行了一项回顾性多中心研究,评估1、5、10和15年OS以及潜在的预后相关因素。
■这项多中心研究已包括40名患者,术后平均随访46.6±58个月。我们观察到25例(62.5%)未住院患者和15例多住院患者(37.5%)。切除后的中位总生存期为48±57.3个月。1年、5年、10年和15年的OS分别为76.2%,63.6%,63.6%,和31.8%。单个骨转移患者15年生存率为82.3%,与0.0%(对数排名,p=0.022)用于多转移性骨患者。
■这项研究主张增加甲状腺癌患者的长期10年OS,切除单个骨转移后,表明这种策略在这个人群中的好处。